VRCDF (Verici Dx) Common Stock : $0.31 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Common Stock?

Verici Dx's quarterly common stock stayed the same from Jun. 2023 ($0.22 Mil) to Dec. 2023 ($0.22 Mil) but then increased from Dec. 2023 ($0.22 Mil) to Jun. 2024 ($0.31 Mil).

Verici Dx's annual common stock increased from Dec. 2021 ($0.18 Mil) to Dec. 2022 ($0.22 Mil) but then stayed the same from Dec. 2022 ($0.22 Mil) to Dec. 2023 ($0.22 Mil).

Verici Dx Common Stock Historical Data

The historical data trend for Verici Dx's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Common Stock Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Common Stock

0.18

0.22

Verici Dx Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Common Stock	Get a 7-Day Free Trial			0.22	0.22	0.22	0.22	0.31

Verici Dx Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

VRCI:UK

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines